Regulatory Updates

Person using a finger prick blood testing medical device

Thailand and Singapore: FDA – HSA Singapore Regulatory Reliance

The Medical Device Control Division, Thai Food and Drug Administration (Thai FDA) of the Ministry of Public Health issued an announcement on the Thailand FDA – HSA Singapore Regulatory Reliance implemented for Class 2-4 IVDs and non-IVDs medical devices effective from 1 June 2022. The registrant in Singapore who obtained

singapore’s health sciences authority (hsa) issues new guidance

Singapore’s Health Sciences Authority (HSA) Issues New Guidance

Health Sciences Authority (HSA) of Singapore has made minor updates to the guidance document titled ‘GN-09: Guidance on the Component Elements of a Dear Healthcare Professional Letter Revision 3.6’. This guidance document takes effect on 09 May 2022. It is now a requirement to include the dealer’s contact information to

guidelines on risk classification of standalone medical mobile applications and qualification of clinical decision support software

Guidelines on Risk Classification of Standalone Medical Mobile Applications and Qualification of Clinical Decision Support Software

The Health Sciences Authority Singapore published a new guidance document titled ‘Guidelines on Risk Classification of Standalone Medical Mobile Applications and Qualification of Clinical Decision Support Software (CDSS). It was published in April 2022. This final version overrides an earlier draft that was sent for industry feedback in 2021.  Standalone

Sign up for our regulatory roundup delivered once a month to your inbox

Scroll to Top

Contact Us

Contact Form Demo

Don’t miss a single regulatory shift in Southeast Asia!

Subscribe to our Newsletter
Be the first to know about critical medical device regulation changes, market entry requirements, and industry shifts.

Subscription Form